JP2017002083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017002083A5 JP2017002083A5 JP2016196955A JP2016196955A JP2017002083A5 JP 2017002083 A5 JP2017002083 A5 JP 2017002083A5 JP 2016196955 A JP2016196955 A JP 2016196955A JP 2016196955 A JP2016196955 A JP 2016196955A JP 2017002083 A5 JP2017002083 A5 JP 2017002083A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- individual
- nanoparticles
- blood vessels
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 62
- 210000004204 blood vessel Anatomy 0.000 claims 16
- 239000002105 nanoparticle Substances 0.000 claims 15
- 102000009027 Albumins Human genes 0.000 claims 9
- 108010088751 Albumins Proteins 0.000 claims 9
- 238000002347 injection Methods 0.000 claims 9
- 239000007924 injection Substances 0.000 claims 9
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 9
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 9
- 229960002930 sirolimus Drugs 0.000 claims 9
- 210000001367 artery Anatomy 0.000 claims 6
- 230000002792 vascular Effects 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000007634 remodeling Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 210000001147 pulmonary artery Anatomy 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 210000001627 cerebral artery Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 238000013152 interventional procedure Methods 0.000 claims 1
- 208000030175 lameness Diseases 0.000 claims 1
- 210000002414 leg Anatomy 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 210000002254 renal artery Anatomy 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161518084P | 2011-04-28 | 2011-04-28 | |
| US61/518,084 | 2011-04-28 | ||
| US201161557851P | 2011-11-09 | 2011-11-09 | |
| US61/557,851 | 2011-11-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508146A Division JP6038123B2 (ja) | 2011-04-28 | 2012-04-27 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017157942A Division JP6427641B2 (ja) | 2011-04-28 | 2017-08-18 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017002083A JP2017002083A (ja) | 2017-01-05 |
| JP2017002083A5 true JP2017002083A5 (enExample) | 2017-02-16 |
| JP6196719B2 JP6196719B2 (ja) | 2017-09-13 |
Family
ID=47072793
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508146A Expired - Fee Related JP6038123B2 (ja) | 2011-04-28 | 2012-04-27 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2016196955A Active JP6196719B2 (ja) | 2011-04-28 | 2016-10-05 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2017157942A Expired - Fee Related JP6427641B2 (ja) | 2011-04-28 | 2017-08-18 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2018203038A Pending JP2019011378A (ja) | 2011-04-28 | 2018-10-29 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508146A Expired - Fee Related JP6038123B2 (ja) | 2011-04-28 | 2012-04-27 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017157942A Expired - Fee Related JP6427641B2 (ja) | 2011-04-28 | 2017-08-18 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2018203038A Pending JP2019011378A (ja) | 2011-04-28 | 2018-10-29 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9061014B2 (enExample) |
| EP (1) | EP2701731B1 (enExample) |
| JP (4) | JP6038123B2 (enExample) |
| KR (3) | KR101970342B1 (enExample) |
| CN (3) | CN109172809A (enExample) |
| AU (2) | AU2012249371B2 (enExample) |
| BR (1) | BR112013027674A2 (enExample) |
| CA (2) | CA3063641A1 (enExample) |
| ES (1) | ES2819204T3 (enExample) |
| IL (2) | IL229041B (enExample) |
| MX (1) | MX354216B (enExample) |
| SG (2) | SG194623A1 (enExample) |
| WO (1) | WO2012149451A1 (enExample) |
| ZA (1) | ZA201307875B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6302875B1 (en) | 1996-10-11 | 2001-10-16 | Transvascular, Inc. | Catheters and related devices for forming passageways between blood vessels or other anatomical structures |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US10441747B2 (en) | 2002-01-22 | 2019-10-15 | Mercator Medsystems, Inc. | Methods and systems for inhibiting vascular inflammation |
| US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
| US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
| US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
| US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
| US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
| US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
| US7803168B2 (en) | 2004-12-09 | 2010-09-28 | The Foundry, Llc | Aortic valve repair |
| AU2012201568B2 (en) * | 2005-02-18 | 2014-07-31 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN103169729A (zh) | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| US9675578B2 (en) | 2006-12-14 | 2017-06-13 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| KR101764439B1 (ko) | 2009-04-22 | 2017-08-02 | 머케이터 메드시스템즈, 인크. | 국소 혈관 운반으로 고혈압을 치료하는 구아네티딘의 용도 |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| US20120259269A1 (en) | 2011-04-08 | 2012-10-11 | Tyco Healthcare Group Lp | Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery |
| AU2012249371B2 (en) | 2011-04-28 | 2017-06-08 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| PL2790675T3 (pl) | 2011-12-14 | 2019-12-31 | Abraxis Bioscience, Llc | Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP2964329B1 (en) | 2013-03-08 | 2019-12-25 | The Regents of The University of California | Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use |
| JP6349381B2 (ja) | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| JP6309610B2 (ja) | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
| US10550187B2 (en) | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| SMT202100642T1 (it) | 2015-06-29 | 2022-03-21 | Abraxis Bioscience Llc | Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi |
| EP3515452B1 (en) * | 2016-09-22 | 2023-09-13 | Mercator Medsystems, Inc. | Treatment of restenosis using temsirolimus |
| KR102475256B1 (ko) * | 2016-09-28 | 2022-12-08 | 아브락시스 바이오사이언스, 엘엘씨 | 미토콘드리아 및 대사 장애를 치료하는 방법 |
| WO2018218182A1 (en) | 2017-05-26 | 2018-11-29 | Mercator Medsystems, Inc. | Combination therapy for treatment of restenosis |
| US11116561B2 (en) | 2018-01-24 | 2021-09-14 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, agents, and associated methods for selective modulation of renal nerves |
| CN111760174B (zh) | 2018-03-14 | 2023-08-25 | 墨卡托医疗系统公司 | 用于局部药物递送的医疗器械和医疗方法 |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| JP7335123B2 (ja) * | 2019-10-07 | 2023-08-29 | 株式会社日本触媒 | 樹脂組成物、硬化性組成物、塗膜付き物品、塗膜付き物品の製造方法、コーティング剤及び積層塗膜付き基材の製造方法 |
| IL292439B2 (en) | 2019-10-28 | 2026-05-01 | Abraxis Bioscience Llc | Pharmaceutical preparations of albumin and rapamycin |
| US20260137665A1 (en) | 2022-10-11 | 2026-05-21 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| CA2155947C (en) | 1993-02-22 | 2007-08-21 | Mark W. Grinstaff | Methods for in vivo delivery of biologics and compositions useful therefor |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| CN1331321A (zh) | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人丝/苏氨酸蛋白激酶16.17和编码这种多肽的多核苷酸 |
| CA2434972C (en) | 2001-01-16 | 2010-06-08 | Vascular Therapies, Llc | Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
| US6547303B1 (en) | 2001-08-13 | 2003-04-15 | Johnson Controls Technology Company | Pivoting seating system |
| US6860867B2 (en) | 2001-09-20 | 2005-03-01 | The Regents Of The University Of California | Method of interventional surgery |
| US20060189941A1 (en) * | 2002-01-22 | 2006-08-24 | Mercator Medsystems, Inc. | Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation |
| US7744584B2 (en) | 2002-01-22 | 2010-06-29 | Mercator Medsystems, Inc. | Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation |
| WO2003061731A2 (en) | 2002-01-22 | 2003-07-31 | Endobionics, Inc. | Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia |
| US20030207907A1 (en) * | 2002-05-03 | 2003-11-06 | Iversen Patrick L. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
| DE10244847A1 (de) * | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
| AU2003275263A1 (en) * | 2002-09-26 | 2004-04-19 | Angiotech International Ag | Perivascular wraps |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| US20040213770A1 (en) | 2003-04-22 | 2004-10-28 | Endobionics, Inc. | Methods and systems for treating ischemic cardiac and other tissues |
| US8003122B2 (en) | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
| EP1758633B1 (en) | 2004-05-13 | 2015-03-18 | Medtronic Vascular, Inc. | Methods for compounding a therapeutic agent to the adventitia of a vessel |
| AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| US7727554B2 (en) | 2004-12-21 | 2010-06-01 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Sustained-release nanoparticle compositions and methods for using the same |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN103169729A (zh) | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| WO2006124739A1 (en) | 2005-05-16 | 2006-11-23 | Novartis Ag | The use of rapamycin derivatives for the treatment and/or prevention of cardiovascular disorders |
| CN101878757A (zh) | 2005-06-21 | 2010-11-10 | 渗透治疗有限公司 | 用于增强血管通路的方法和组合物 |
| US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| CN101291658B (zh) | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
| WO2008016602A2 (en) * | 2006-07-31 | 2008-02-07 | Neurosystec Corporation | Free base gacyclidine nanoparticles |
| US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| US9675578B2 (en) | 2006-12-14 | 2017-06-13 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| EP3417859A1 (en) | 2007-03-07 | 2018-12-26 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
| WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
| US9044385B2 (en) * | 2007-05-16 | 2015-06-02 | Abbott Cardiovascular Systems Inc. | Therapeutic compositions for targeted vessel delivery |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| EP2222281B1 (en) * | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| AU2009324464B2 (en) | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| BRPI1008955A2 (pt) | 2009-03-13 | 2015-09-01 | Abraxis Bioscience Llc | Terapia de combinação com derivados de tiocolchicina. |
| MX2011010673A (es) | 2009-04-10 | 2012-02-21 | Abraxis Bioscience Llc | Formulaciones de nanoparticulas y usos de las mismas. |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| KR101764439B1 (ko) * | 2009-04-22 | 2017-08-02 | 머케이터 메드시스템즈, 인크. | 국소 혈관 운반으로 고혈압을 치료하는 구아네티딘의 용도 |
| BR112012004149A2 (pt) | 2009-08-25 | 2016-03-22 | Abraxis Bioscience Llc | terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| US9096660B2 (en) * | 2010-04-26 | 2015-08-04 | Abraxis Bioscience, Llc | SPARC binding antibodies and uses thereof |
| CN103221042B (zh) | 2010-06-02 | 2016-02-10 | 阿布拉科斯生物科学有限公司 | 治疗膀胱癌的方法 |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| CA2801891C (en) | 2010-06-07 | 2020-10-27 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| AU2012249371B2 (en) | 2011-04-28 | 2017-06-08 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| PL2790675T3 (pl) | 2011-12-14 | 2019-12-31 | Abraxis Bioscience, Llc | Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| JP6349381B2 (ja) | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| CN105209035A (zh) | 2013-03-13 | 2015-12-30 | 阿布拉科斯生物科学有限公司 | 治疗儿童实体瘤的方法 |
| JP6309610B2 (ja) | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
| US20170202782A1 (en) | 2014-04-06 | 2017-07-20 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| US20180064679A1 (en) | 2015-03-05 | 2018-03-08 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
| SMT202100642T1 (it) | 2015-06-29 | 2022-03-21 | Abraxis Bioscience Llc | Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi |
| US20180177771A1 (en) | 2015-06-29 | 2018-06-28 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
| CA2990705A1 (en) | 2015-06-29 | 2017-01-05 | Abraxis Bioscience, Llc | Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy |
| JP2018521058A (ja) | 2015-06-29 | 2018-08-02 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法 |
| US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
-
2012
- 2012-04-27 AU AU2012249371A patent/AU2012249371B2/en active Active
- 2012-04-27 EP EP12777153.3A patent/EP2701731B1/en active Active
- 2012-04-27 ES ES12777153T patent/ES2819204T3/es active Active
- 2012-04-27 WO PCT/US2012/035626 patent/WO2012149451A1/en not_active Ceased
- 2012-04-27 CA CA3063641A patent/CA3063641A1/en not_active Abandoned
- 2012-04-27 KR KR1020137031161A patent/KR101970342B1/ko active Active
- 2012-04-27 CN CN201810882369.8A patent/CN109172809A/zh active Pending
- 2012-04-27 SG SG2013079264A patent/SG194623A1/en unknown
- 2012-04-27 CA CA2834040A patent/CA2834040C/en active Active
- 2012-04-27 SG SG10201606406PA patent/SG10201606406PA/en unknown
- 2012-04-27 MX MX2013012458A patent/MX354216B/es active IP Right Grant
- 2012-04-27 CN CN201280032010.2A patent/CN103648521A/zh active Pending
- 2012-04-27 US US14/113,568 patent/US9061014B2/en active Active
- 2012-04-27 BR BR112013027674A patent/BR112013027674A2/pt not_active Application Discontinuation
- 2012-04-27 KR KR1020197010659A patent/KR102108959B1/ko active Active
- 2012-04-27 JP JP2014508146A patent/JP6038123B2/ja not_active Expired - Fee Related
- 2012-04-27 CN CN201811222358.3A patent/CN109288789A/zh active Pending
- 2012-04-27 KR KR1020207012800A patent/KR20200051841A/ko not_active Ceased
-
2013
- 2013-10-22 ZA ZA2013/07875A patent/ZA201307875B/en unknown
- 2013-10-24 IL IL229041A patent/IL229041B/en active IP Right Grant
-
2015
- 2015-05-15 US US14/714,131 patent/US9884013B2/en not_active Expired - Fee Related
-
2016
- 2016-10-05 JP JP2016196955A patent/JP6196719B2/ja active Active
-
2017
- 2017-08-18 JP JP2017157942A patent/JP6427641B2/ja not_active Expired - Fee Related
- 2017-09-06 AU AU2017225031A patent/AU2017225031B2/en active Active
- 2017-12-21 US US15/851,478 patent/US10258565B2/en active Active
-
2018
- 2018-10-29 JP JP2018203038A patent/JP2019011378A/ja active Pending
-
2019
- 2019-02-25 US US16/284,995 patent/US20190183789A1/en not_active Abandoned
-
2020
- 2020-01-28 IL IL272313A patent/IL272313A/en unknown
- 2020-06-12 US US16/900,565 patent/US20200306180A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515028A5 (enExample) | ||
| JP2020521755A5 (enExample) | ||
| JP2015518897A5 (enExample) | ||
| Liu et al. | Additive benefit of glycoprotein IIb/IIIa inhibition and adjunctive thrombus aspiration during primary coronary intervention: results of the Initial Thrombosuction and Tirofiban Infusion (ITTI) trial | |
| Kitamura et al. | Transient sinus node dysfunction following sinus node artery occlusion due to radiofrequency catheter ablation of the septal superior vena cava–right atrium junction | |
| De Gregorio et al. | Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease | |
| Al-Hijji et al. | Revascularization for left main and multivessel coronary artery disease: current status and future prospects after the EXCEL and NOBLE Trials | |
| Ateş et al. | Acute coronary syndrome due to midazolam use: Kounis syndrome during a transurethral prostatectomy | |
| Tsuji | Four-year follow-up of the biodegradable stent (Igaki-Tamai stent) | |
| Colucci | Overview of the therapy of heart failure due to systolic dysfunction | |
| Koutouzis et al. | Percutaneous coronary intervention facilitated by extracorporeal membrane oxygenation support in a patient with cardiogenic shock | |
| Wei et al. | Giant right sinus of Valsalva aneurysm led to proximal right coronary artery occlusion. | |
| Biernawska et al. | Electrophysiological, hemodynamic, and metabolic response to open procedure or endovascular repair of infrarenal aortic aneurysms | |
| Gülşen et al. | Coronary vasospasm-induced periodic ventricular fibrillation and successful ablation through coronary stenting | |
| Allen | State of the art in cardiac intervention: A case report | |
| Lee et al. | Cardiopulmonary resuscitation with assisted extracorporeal life support during cardiac arrest caused by drug-eluting stent thrombosis: a case report | |
| CN202843855U (zh) | 一种新型冠状动脉血管支架 | |
| Kolesnichenko et al. | Modeling L-name induced nitric oxide deficiency considering the the cardio-and endothelial protective effects | |
| Karabay et al. | Coronary muscular bridge mimicking acute stent thrombosis: online article | |
| de la Torre Hernandez et al. | Update on interventional cardiology | |
| Ngow et al. | Anterior Myocardial Infarction Associated with Myocardial Bridging in a Young Man | |
| Yamada et al. | Reply to letter to the editor:“A potential and lionhearted soldier for atrial fibrillation accompanied with heart failure: Renal denervation” | |
| Mangialavori et al. | Subclavian steal syndrome presenting as recurrent pulmonary oedema associated with acute left ventricular diastolic dysfunction | |
| Saxena et al. | Non-cardiac surgery 2 weeks after percutaneous cardiac intervention | |
| Kılıç et al. | A severe aortic coarctation newly diagnosed during cardiac catheterization in an adult presenting with acute anterior myocardial infarction |